Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration.

BACKGROUND Antiretroviral therapy (ART)-mediated immune reconstitution fails to restore the capacity of the immune system to spontaneously control human immunodeficiency virus (HIV) replication. METHODS A total of 23 HIV type 1 (HIV-1)-infected, virologically suppressed subjects receiving ART (CD4(+) T-cell count, >450 cells/μL) were randomly assigned to have 180 μg/week (for arm A) or 90 μg/week (for arm B) of pegylated (Peg) interferon alfa-2a added to their current ART regimen. After 5 weeks, ART was interrupted, and Peg-interferon alfa-2a was continued for up to 12 weeks (the primary end point), with an option to continue to 24 weeks. End points included virologic failure (viral load, ≥ 400 copies/mL) and adverse events. Residual viral load and HIV-1 DNA integration were also assessed. RESULTS At week 12 of Peg-interferon alfa-2a monotherapy, viral suppression was observed in 9 of 20 subjects (45%), a significantly greater proportion than expected (arm A, P = .0088; arm B, P = .0010; combined arms, P < .0001). Over 24 weeks, both arms had lower proportions of subjects who had viral load, compared with the proportion of subjects in a historical control group (arm A, P = .0046; arm B, P = .0011). Subjects who had a sustained viral load of <400 copies/mL had decreased levels of integrated HIV DNA (P = .0313) but increased residual viral loads (P = .0078), compared with subjects who experienced end-point failure. CONCLUSIONS Peg-interferon alfa-2a immunotherapy resulted in control of HIV replication and decreased HIV-1 integration, supporting a role for immunomediated approaches in HIV suppression and/or eradication. CLINICAL TRIALS REGISTRATION NCT00594880.

[1]  E. Ruiz-Mateos,et al.  Plasmacytoid Dendritic Cells Reduce HIV Production in Elite Controllers , 2012, Journal of Virology.

[2]  J. Fellay,et al.  Role of retroviral restriction factors in the interferon-α–mediated suppression of HIV-1 in vivo , 2012, Proceedings of the National Academy of Sciences.

[3]  F. Bushman,et al.  Engineering HIV-Resistant Human CD4+ T Cells with CXCR4-Specific Zinc-Finger Nucleases , 2011, PLoS pathogens.

[4]  J. Singer,et al.  A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune , 2011, AIDS.

[5]  M. Carrington,et al.  HLA/KIR restraint of HIV: surviving the fittest. , 2011, Annual review of immunology.

[6]  C. Dinarello,et al.  Histone Deacetylase Inhibitors for Purging HIV-1 from the Latent Reservoir , 2011, Molecular medicine.

[7]  D. Sullivan,et al.  Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. , 2011, The Journal of general virology.

[8]  S. Migueles,et al.  Elite Suppressors Harbor Low Levels of Integrated HIV DNA and High Levels of 2-LTR Circular HIV DNA Compared to HIV+ Patients On and Off HAART , 2011, PLoS pathogens.

[9]  C. Rouzioux,et al.  Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial , 2011, AIDS.

[10]  A. McMichael,et al.  First-Class Control of HIV-1 , 2010, Science.

[11]  Jeffrey N. Martin,et al.  Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals , 2010, AIDS.

[12]  M. Altfeld,et al.  Innate immune activation in primary HIV-1 infection. , 2010, The Journal of infectious diseases.

[13]  D. Heckerman,et al.  Additive Contribution of HLA Class I Alleles in the Immune Control of HIV-1 Infection , 2010, Journal of Virology.

[14]  M. Malim,et al.  Characterization of the Alpha Interferon-Induced Postentry Block to HIV-1 Infection in Primary Human Macrophages and T Cells , 2010, Journal of Virology.

[15]  R. Schooley,et al.  Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. , 2010, The Journal of infectious diseases.

[16]  Kristen K. Dang,et al.  Genome-Wide mRNA Expression Correlates of Viral Control in CD4+ T-Cells from HIV-1-Infected Individuals , 2010, PLoS pathogens.

[17]  L. Montaner,et al.  Inability of Plasmacytoid Dendritic Cells To Directly Lyse HIV-Infected Autologous CD4+ T Cells despite Induction of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand , 2009, Journal of Virology.

[18]  D. Ge,et al.  HLA-C cell surface expression and control of HIV / AIDS correlate with a variant upstream of HLA-C , 2009 .

[19]  N. Mehra,et al.  Genetic determinants of HIV-1 infection and progression to AIDS: immune response genes. , 2009, Tissue antigens.

[20]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[21]  C. Hallahan,et al.  Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. , 2008, Immunity.

[22]  Jeffrey N. Martin,et al.  Evidence for Persistent Low-Level Viremia in Individuals Who Control Human Immunodeficiency Virus in the Absence of Antiretroviral Therapy , 2008, Journal of Virology.

[23]  H. Schuitemaker,et al.  HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy , 2008, AIDS.

[24]  B. Walker,et al.  Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452) , 2008, AIDS.

[25]  A. Boasso,et al.  Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. , 2008, Clinical immunology.

[26]  P. Narciso,et al.  Interferon may prevent HIV viral rebound after HAART interruption in HIV patients. , 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[27]  L. Montaner,et al.  NK Cell Lysis of HIV-1-Infected Autologous CD4 Primary T Cells: Requirement for IFN-Mediated NK Activation by Plasmacytoid Dendritic Cells1 , 2007, The Journal of Immunology.

[28]  J. Lawrence,et al.  A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). , 2006, The Journal of infectious diseases.

[29]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[30]  D. Katzenstein,et al.  A Pilot Study Evaluating Time to CD4 T-cell Count <350 cells/mm3 After Treatment Interruption Following Antiretroviral Therapy ± Interleukin 2: Results of ACTG A5102 , 2006, Journal of acquired immune deficiency syndromes.

[31]  J. Clot,et al.  The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon‐α treatment , 2005, The British journal of dermatology.

[32]  Tara L. Kieffer,et al.  Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. , 2005, JAMA.

[33]  L. Montaner,et al.  Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection , 2004, PLoS medicine.

[34]  J. Kahn,et al.  HIV RNA testing in the context of nonoccupational postexposure prophylaxis. , 2004, The Journal of infectious diseases.

[35]  J. Clot,et al.  Interferon-α restores HIV-induced alteration of natural killer cell perforin expression in vivo , 2003 .

[36]  J. Clot,et al.  Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivo. , 2003, AIDS.

[37]  L. Mimms,et al.  Sensitive detection of genetic variants of HIV-1 and HCV with an HIV-1/HCV assay based on transcription-mediated amplification. , 2002, Journal of virological methods.

[38]  F. Gheyas,et al.  Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. , 2001, Blood.

[39]  R. Lempicki,et al.  HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  V. Calvez,et al.  HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. , 1999, AIDS.

[41]  T. Chun,et al.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[44]  M. Baseler,et al.  ANTI-RETROVIRAL EFFECTS OF INTERFERON-α IN AIDS-ASSOCIATED KAPOSI'S SARCOMA , 1988, The Lancet.

[45]  J. Metcalf,et al.  Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. , 1988, Lancet.

[46]  E Wetzler,et al.  Letter: Type-iv hyperlipidaemia. , 1975, Lancet.